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Purpose
The FDA TLOVR algorithm has been commonly used
to assess virologic response to antiretroviral (ARV) regi-
mens. The FDA Snapshot algorithm has been proposed
to replace the TLOVR algorithm, as it is simpler and is
expected to yield similar results. Multiple studies deter-
mined that efficacy of LPV/r dosed once-daily (QD) +
nucleoside reverse transcriptase inhibitors (NRTIs) was
statistically similar to LPV/r dosed twice-daily (BID) +
NRTIs using the FDA TLOVR algorithm. The purpose
of the analyses presented here is to compare the
TLOVR and Snapshot algorithms in the context of stu-
dies evaluating QD vs. BID LPV/r-based regimens.
Methods
Three studies comparing LPV/r QD + NRTIs vs. LPV/r
BID + NRTIs in ARV-naïve (Study 418, n=190; Study
730, n=664) or ARV-experienced (Study 802, n=599)
subjects were analyzed. Study results through 48 and 96
weeks were compared using the FDA TLOVR and FDA
Snapshot algorithms. The Snapshot algorithm differs
from the TLOVR algorithm primarily in its focus only
on the visit of interest: a subject is a responder if and
only if the subject has an HIV-1 RNA level <50 copies/
mL at the visit of interest.
Results
In the comparison of the FDA TLOVR algorithm to the
FDA Snapshot algorithm, 59/1453 (4%) subjects had dis-
cordant results (responder by one algorithm but not the
other) at week 48, as did 28/854 (3%) at week 96. In
each study, LPV/r QD-based regimens provided similar
virologic response rates to LPV/r BID-based regimens
for each analysis algorithm at each visit (Table 1).
Conclusions
The FDA Snapshot analysis is easier to understand, sim-
pler to calculate, and gives similar results compared to
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Table 1 Percent of subjects with HIV-1 RNA <50 copies/mL using FDA TLOVR and Snapshot algorithms
Week Analysis Algorithm Study 418 Study 730 Study 802
QD (n=115) BID (n=75) QD (n=333) BID (n=331) QD (n=300) BID (n=299)
48 TLOVR 71% 65% 78% 77% 55% 52%
48 Snapshot 70% 64% 80% 78% 57% 54%
96 TLOVR 57% 55% 63% 64% n/a n/a
96 Snapshot 57% 55% 65% 69% n/a n/a
n/a not available, 48-week study
P>0.05 for all QD vs. BID comparisons within each study, analysis algorithm, and timepoint
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LPV/r QD-based vs. BID-based regimens in ARV-naïve
subjects as well as ARV-experienced subjects, irrespec-
tive of timepoint or analysis algorithm.
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